Timeline Staleness Signal

Anlotinib combined Docetaxel

Anlotinib combined Docetaxel is flagged as timeline staleness signal because public records show timeline staleness. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.

Program overview

Context

Indication: Non-small Cell Lung Cancer

Mechanism: Unknown

Modality: Unknown

Sponsor: Yong Fang

Scores

Risk-signal summary

Registry: 3/5

Timeline: 3/5

Recruitment burden: 1/5

Results availability: 0/5

Program risk: 4/5

Evidence

Public links

https://clinicaltrials.gov/study/NCT03726736

Linked trials

Trial-level signal details

TrialStatusTimelineResultsBurden
NCT03726736Unknown Status Signal (UNKNOWN)stale_update_signal | primary_completion_date_past_signal | completion_date_past_signalLow Signalrare_population_signal